SREBF2 and metabolic dysfunction-associated steatotic liver disease: In humans with NAFLD, hepatic expression of SREBF2 and its target genes was upregulated, with the degree of SREBF2 activation paralleling the severity of hepatic cholesterol overload [35, 36].